All
  • All
  • ELISA Kit
  • Protein
  • Antibody
  • Molecular Biology Product
  • Small Molecule
  • Peptide
All
  • All
  • ELISA Kit
  • Protein
  • Antibody
  • Molecular Biology Product
  • Small Molecule
  • Peptide

CLEC2D (ZM-008 Biosimilar) Recombinant Monoclonal Antibody

Datasheet
Code CSB-RA883401MB1HU
Size US$9799
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Q9UHP7
Target Names
CLEC2D
Alternative Names
ZM008 research-grade biosimilar; ZM-008 research-grade biosimilar ;CLEC2D antibody; CLAX antibody; LLT1 antibody; OCIL antibody; C-type lectin domain family 2 member D antibody; Lectin-like NK cell receptor antibody; Lectin-like transcript 1 antibody; LLT-1 antibody; Osteoclast inhibitory lectin antibody
Species Reactivity
Human
Immunogen
Recombinant Human CLEC2D protein
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Clonality
Monoclonal
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
0.01M PBS，pH7.4
Form
Liquid
Troubleshooting and FAQs
Antibody FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Notes
Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity > 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.
Lead Time
3-4 weeks
Description

This recombinant monoclonal antibody is developed as a research-grade biosimilar to the reference antibody ZM-008, targeting CLEC2D (C-type lectin domain family 2 member D), also known as LLT1 (lectin-like transcript 1). CLEC2D functions as an inhibitory ligand expressed on activated lymphocytes, antigen-presenting cells, and certain tumor cells. It binds to the inhibitory receptor CD161 (KLRB1) on natural killer cells and T cells, delivering immunosuppressive signals that dampen cellular immune responses. This interaction plays a critical role in immune regulation and self-tolerance, but can also facilitate immune evasion in pathological contexts. CLEC2D expression has been implicated in various cancers, autoimmune disorders, and viral infections, where it contributes to the modulation of immune surveillance and inflammatory responses.

As a biosimilar to ZM-008, this antibody serves as a valuable tool for investigating CLEC2D expression patterns, protein localization, and functional roles in immune regulation and disease pathogenesis. It enables researchers to explore the CLEC2D-CD161 axis in tumor immunology, transplantation immunity, and chronic inflammatory conditions, supporting studies aimed at understanding immune checkpoint mechanisms and developing novel immunotherapeutic strategies.

Usage
It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

Related Products

CLEC2D Antibodies

CLEC2D Proteins

CLEC2D ELISA kits

Customer Reviews and Q&A

■ Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Receptor for KLRB1 that protects target cells against natural killer cell-mediated lysis. Inhibits osteoclast formation. Inhibits bone resorption. Modulates the release of interferon-gamma. Binds high molecular weight sulfated glycosaminoglycans.
Gene References into Functions
  1. These results show that susceptibility of normal articular chondrocytes to lysis by NK cells is modulated by NKR-P1A/LLT1 interactions. Thus, NKR-P1A/LLT1 interaction might provide some novel target for therapeutic interventions in the course of pathological cartilage injury. PMID: 29212911
  2. Blocking LLT1-NKRP1A interaction will make prostate cancer cells susceptible to killing by NK cells, suggesting a therapeutic option for treatment of prostate cancer. PMID: 27626681
  3. these data suggest that LLT1-CD161 interactions play a novel and important role in B cell maturation within the Germinal center in humans. PMID: 26829983
  4. In RA joints, LLT1 is expressed by cells of the monocyte/macrophage lineage. PMID: 26147876
  5. The hexamer of glycosylated LLT1 consists of three classical dimers. The hexameric packing may indicate a possible mode of interaction of C-type lectin-like proteins in the glycosylated form. PMID: 25760607
  6. One polymorphism in LLT1 was found to be associated with our Crohn's Disease population (P<0.034).Our Ulcerative Colitis cohort was not associated with the variation in LLT1 (P=0.33) PMID: 22664939
  7. LLT1 and CD161 have roles in modulating immune responses to pathogens; and interferon-gamma contributes to modulate immune responses PMID: 21930700
  8. Molecular basis for LLT1 protein recognition by human CD161 protein (NKRP1A/KLRB1). PMID: 21572041
  9. Data show that only CLEC2D isoform 1 (LLT1) is expressed on the cell surface. PMID: 20843815
  10. LLT1 used Src-PTK, p38 and ERK signalling pathways, but not PKC, PI3K or calcineurin pathways, to increase production of IFN-gamma by human natural killer cells. PMID: 20415786
  11. LLT1 induces Interferon Type II production by natural killer cells. PMID: 15104121
  12. Data show that osteoclast inhibitory lectin (OCIL) binds a range of physiologically important glycosaminoglycans, and this property may modulate OCIL actions upon other cells [OCIL]. PMID: 15123656
  13. Engagement of CD161 on NK cells with LLT1 expressed on target cells inhibited NK cell-mediated cytotoxicity and IFN-gamma secretion. LLT1/CD161 interaction in the presence of a TCR signal enhanced IFN-gamma production by T cells PMID: 16339512
  14. LLT1 on target cells can inhibit NK cytotoxicity via interactions with CD161. LLT1 activates NFAT-GFP reporter cells expressing a CD3zeta-CD161 chimeric receptor; reciprocally, reporter cells with a CD3zeta-LLT1 chimeric receptor are stimulated by CD161 PMID: 16339513
  15. Expression of LLT1 on activated dendritic cells and B cells suggests that it might regulate the cross-talk between NK cells and APCs PMID: 18453569
  16. Women with a lysine (GG genotype) at position 19 of the OCIL protein displayed lower bone mineral density at femoral neck and at lumbar spine sites than women having an asparagine residue. PMID: 18465072

Show More

Hide All

Subcellular Location
Cell membrane; Single-pass type II membrane protein.; [Isoform 2]: Endoplasmic reticulum.; [Isoform 4]: Endoplasmic reticulum.
Tissue Specificity
Detected in peripheral blood leukocytes, osteoblasts, lymph node, thymus and spleen. Isoform 1, isoform 2 and isoform 4 are expressed in T- and B-lymphocytes, and at lower levels in NK cells. They are also expressed in B-cell lines and LPS-matured monocyt
Database Links

HGNC: 14351

OMIM: 605659

KEGG: hsa:29121

UniGene: Hs.268326

Promotions
Reward For Reviews
Free antibody trial
Contact Us

  Email: [email protected]
  Distributors Worldwide

Service

Phage Display Service

Antibody Service

Protein Service

Gene Synthesis Service

Oligo Synthesis Service

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of email
Email
[email protected]
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2026 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Privacy Policy
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*